ABSTRACT
In current practice, estrogen receptor (ER), gross cystic disease fluid protein 15 (GCDFP-15), and mammaglobin A (MGB) serve as breast-specific immunomarkers in the workup of tumors of unknown primary. [1] [2] [3] [4] [5] However, the sensitivities for GCDFP-15 and MGB are reported in the ranges of 35% to 55% and 65% to 70%, respectively. Our unpublished data on tissue microarray (TMA) sections of 250 cases of invasive breast carcinomas, including ductal, lobular, and other special types, is even lower: 30% for GCDFP-15 and 50% for MGB, which is similar to the reports by Bhargava et al, 2 who found GCDFP-15 expression in 23.1% and MGB expression in 55.4% of breast carcinomas, and by Lewis et al, 5 who reported GCDFP-15 labeling of 37% and MGB labeling of 54% in breast carcinomas. The rate of ER-negative metastatic breast carcinoma is reported in the range of 40% to 52%. [6] [7] [8] [9] [10] [11] [12] [13] Given the frequent absence of expression of currently available breast-specific immunomarkers (such as ER, Upon completion of this activity you will be able to:
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GCDFP-15, and MGB) in metastatic breast carcinomas, studies to discover newer breast-specific immunomarkers were undertaken. NY-BR-1 and GATA-binding protein 3 (GATA-3) are among the most promising immunomarkers. NY-BR-1 is a mammary differentiation antigen expressed in normal mammary tissue and its malignant counterpart, with a predominantly cytoplasmic staining pattern. Its mRNA expression on reverse transcriptase polymerase chain reaction is restricted to carcinomas of the breast, testis, and prostate. [14] [15] [16] Its expression in breast carcinomas was reported as 58.4% by Woodard et al 17 and 46.6% by Balafoutas et al 18; however, NY-BR-1 expression is strongly associated with ER expression in both studies. Its expression in ER-negative breast carcinomas was reported as much lower, 18% and 28.4%, respectively.
GATA-3 is one of six members of a subfamily of zinc finger transcription factors, plays an important role in cell-fate specification, and has recently emerged as a critical determinant of luminal epithelial cell differentiation in the adult mammary gland. GATA-3 is highly expressed in luminal A breast carcinomas. 19, 20 Previously, we had studied GATA-3 expression in 1,110 cases of various human carcinomas and 310 cases of normal tissues using immunohistochemical analysis of TMA sections. We concluded that GATA-3 is a sensitive and specific marker for breast and urothelial carcinomas. 21 In the current study, we used immunohistochemical analysis to further investigate the expression of GATA-3 in 96 ER-negative breast carcinomas, including 49 TMA cases and 47 consecutive core needle biopsy (CNB) specimens. In addition, immunoassays of GCDFP-15 and MGB were also performed for comparison. The aims of this study are to investigate the expression of GATA-3 in ER-negative breast carcinomas, to compare it with other breast-specific markers, and ultimately to evaluate its diagnostic usefulness as a breast-specific immunomarker in the workup of tumors of unknown primary.
Materials and Methods

Construction of TMA Block
The study was approved by the institutional review board at Geisinger Medical Center (Danville, PA). Forty-nine cases of ER-negative primary breast carcinomas, including invasive ductal carcinoma (IDC) grade 2 (n = 21), IDC grade 3 (n = 22), and others (n = 6, including 2 metaplastic, 2 medullary, and 2 apocrine carcinomas), were retrieved from the surgical pathology archives at Geisinger Medical Center from 2000 to 2009. These samples include 39 Her2/neu-negative and 10 Her2/neu-positive cases. A TMA block with two punches of 1.0 mm each for each case was constructed as previously described. 22, 23 The ER-negative status is defined by ER immunostaining on TMA sections using the current guideline (<1%). The tumor grading is based on the Nottingham combined histologic grade (Elston-Ellis modification of Scarff-Bloom-Richardson grading system).
CNB Cases
Forty-seven consecutive ER-negative CNB cases were retrieved from the archives of the Department of Laboratory Medicine at Geisinger Medical Center from 2010 to 2011, including IDC grade 2 (n = 8), IDC grade 3 (n = 30), metaplastic carcinomas (n = 4), carcinoma with medullary features (n = 1), and carcinoma with apocrine features (n = 4). Thirty-seven cases were Her2/neu negative and 10 were Her2/neu positive.
Immunohistochemical Analysis
Immunohistochemical analysis was performed to study GATA-3 (Biocare Medical, Concord, CA), GCDFP-15 (Cell Marque Corp, Rocklin, CA), and MGB (Ventana Medical Systems, Tucson, AZ) expression in 49 TMA and 47 CNB specimens of ER-negative breast carcinomas. The Dako staining system (1:25 dilution, ethylenediaminetetraacetic acid antigen retrieval, and 45-minute incubation for primary antibody; Dako, Carpinteria, CA) was used as described previously. 24, 25 The staining intensity was graded as weak or strong. The distribution for GATA-3 was recorded as negative (<5% of tumor cell nuclei stained), 1+ (5%-25%), 2+ (26%-50%), 3+ (51%-75%), or 4+ (>75%); for MGB and GCDFP-15, any cytoplasmic staining was defined as positive. Two surgical pathologists (H.L. and F.L.) independently evaluated the immunostained slides. Any discrepancies between the staining results of the two pathologists were resolved by discussion at a multihead microscope.
Results
GATA-3 Expression in 96 ER-Negative Breast Carcinomas
GATA-3 expression was demonstrated in 69% (66/96) of ER-negative breast carcinomas, including 59% (29/49) of TMA and 79% (37/47) of CNB cases. The majority of GATA-3-positive cases (73%) showed a strong and diffuse (4+ or 3+) nuclear staining pattern ❚Image 1A❚ and ❚Image 1B❚. Of the six metaplastic carcinomas, only one (17%) showed weak 2+ staining ❚Image 1C❚ and ❚Image 1D❚. Similarly, one of the three (33%) carcinomas with medullary features showed weak 2+ staining ❚Image 1E❚ and ❚Image 1F❚. The six cases of apocrine carcinomas revealed a heterogeneous staining pattern, from nonreactive (one case) to strong, diffuse, or weak focal 
GCDFP-15 Expression in 96 ER-Negative Breast Carcinomas
GCDFP-15 expression was demonstrated in 15% (14/96) of ER-negative breast carcinomas, including 12% (6/49) of TMA and 17% (8/47) of CNB cases; 83% (5/6) of apocrine carcinomas expressed GCDFP-15 (Image 2D). The six metaplastic carcinomas and three carcinomas with medullary features were all nonreactive. The GCDFP-15 immunostaining results for 96 ER-negative breast carcinomas are summarized in ❚Table 5❚.
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❚Image 2❚ A, Invasive ductal carcinoma of the breast, apocrine type (H&E, ×400). Three (75%) of four apocrine carcinomas are GATA-binding protein 3 (GATA-3) positive, showing heterogeneous patterns, from strong 4+ (B, ×400) to weak 2+ nuclear staining (C, ×400). D, Gross cystic disease fluid protein 15 (GCDFP-15) is expressed in five (83%) of six apocrine carcinomas (×200). 
Discussion
Identifying metastatic breast carcinoma of primary origin can be challenging, especially with ER-negative tumors, which have been reported in nearly half of all metastatic breast carcinomas. In addition to ER, the currently available breastspecific immunomarkers, such as GCDFP-15 and MGB, are usually not expressed in high-grade breast carcinomas, such as basal-like and triple-negative carcinomas. 26, 27 The newer immunomarker, NY-BR-1, was reported to be expressed in 18% and 28.4% of ER-negative breast carcinomas as stated earlier. GATA-3 is emerging as a sensitive and relatively specific marker for breast carcinomas. Several studies reported its high expression in breast and urothelial carcinomas, [28] [29] [30] [31] but its expression in salivary gland tumors and autonomic nervous system tumors was also reported recently. 32, 33 In our previous study, GATA-3 expression was identified in 94% of invasive breast carcinomas (comprising ER-positive and ER-negative cases) and 86% of urothelial carcinomas. However, only a few reports in the literature have explored the expression of GATA-3 in ER-negative tumors, which, indeed, are the most problematic cases in terms of defining breast primary in settings of metastases. For ER-negative breast carcinomas, Yang and Nonaka 34 reported that 6.7% (2/30) and Albergaria et al 35 reported that 17.6% (16/91) expressed GATA-3; CiminoMathews et al 36 found that GATA-3 was expressed in 54% of ER-negative tumors, including 86% of Her2-type, 43% of triple-negative, and 54% of metaplastic carcinomas.
To further investigate the expression of GATA-3 in ER-negative tumors, we conducted an immunohistochemical investigation of GATA-3 expression in 96 ER-negative breast carcinomas. Our study revealed that an overall 69% (66/96) of ER-negative breast carcinomas expressed GATA-3, including 59% (29/49) of TMA and 79% (37/47) of CNB cases. Our data are similar to those of Cimino-Mathews et al 36 : 59% of TMAs in our data compared with their 54% positive rate in TMA cases. Our CNB cases showed a higher expression rate of 79%, which more closely approximates the daily practice of tissue sections. Moreover, the majority of GATA-3-positive cases showed a diffuse and strong nuclear staining pattern, which is significant and can be reliably interpreted. Metaplastic carcinomas and carcinomas with medullary features tended to lack or have markedly decreased GATA-3 expression in our study; however, the number of cases studied is very limited. Cimino-Mathews et al 36 reported that 54% (7/13) of metaplastic carcinomas expressed GATA-3, but the staining was weak, and nearly half of the positive cases showed only 1+ staining. The small number of metaplastic carcinomas may contribute to the lower positive rate in our study; however, the expression of GATA-3 in metaplastic and medullary carcinomas needs to be validated in larger studies.
In contrast, the expression of GCDFP-15 and MGB in ER-negative breast carcinomas was 15% (14/96) and 35% (34/96), respectively, in our current study. Among the 14 cases of GCDFP-15-positive tumors, five were apocrine carcinomas. These data revealed a limited use for GCDFP-15 in the difficult workup of tumors of unknown primary, which are often ER-negative metastases. MGB showed a 35% rate of expression, which is higher than that of GCDFP-15 but still expressing a sensitivity that is relatively low. In addition, MGB is not breast specific. It had been reported in 50% to 66% of gynecologic malignancies, 37-39 similar to our previous study, in which 64% (82/128) of endometrial adenocarcinomas on TMA sections expressed MGB. 40 When dealing with challenging cases, especially in female patients, the differential diagnosis between breast and gynecologic malignancies often arises. The expression of MGB in both tumors makes it less useful in differentiating breast vs gynecologic malignancies. On the other hand, GATA-3 is highly expressed in breast carcinomas, as stated earlier, and expressed only in 2% (2/96) of the endometrial carcinomas and in none of the ovarian serous carcinomas (n = 56) and endocervical adenocarcinomas (n = 17). 21 Compared with the 69% positive rate for GATA-3 in ER-negative tumors and with the majority of positive cases having a diffuse and strong staining pattern, we concluded that GATA-3 is a more sensitive immunomarker for breast primary. Our data, in conjunction with our previous findings of GATA-3 expression in 94% of breast carcinomas and 86% of urothelial carcinomas, demonstrated that GATA-3 is by far the best breast-specific immunomarker. With this relatively high sensitivity and specificity, GATA-3 should be included in the panel of immunomarkers in the workup of tumors of unknown origin.
